BioSpace News Archive

Xylyx Bio today announced findings from an independent clinical study that validated that their proprietary Matrikynes® ingredient is safe and highly effective for anti-aging and other topical skin applications.

PacBio, a leading developer of high-quality, highly accurate sequencing solutions, announced the availability of its new high-throughput Nanobind DNA Extraction kits, another key product from the highly valuable Circulomics acquisition.

Celanese Corporation (NYSE: CE) today announced that it has entered into an agreement with Glaukos Corporation to supply its VitalDose® Drug Delivery Platform for use as a component in Glaukos’ iDose® TR, a micro-invasive intraocular implant designed to lower intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension.

Select Medical announced it has signed an agreement to acquire Vibra Hospital of Richmond, a long-term acute care hospital in Richmond, Virginia.

Chiesi, the research-oriented international biopharmaceutical group headquartered in Parma, recorded a turnover of €2,749 billion in 2022, an increase of 13.6% from 2021.

Biotheryx, Inc. announced it has entered into a Research Collaboration and License agreement with Incyte to discover and develop targeted protein degraders for novel oncology targets.

Endogena Therapeutics Inc., a clinical-stage biotech company focused on the development of endogenous regenerative medicines, announced today that the dose-escalation stage of its phase 1/2a study of EA-2353 in retinitis pigmentosa (RP) has been successfully completed.

OpGen, Inc. reported that it signed an amendment to its research and development collaboration agreement with FIND, to expand the collaboration which was originally started in fall of 2022.

Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced the presentation of two posters at the 55th Gatlinburg Conference, being held April 10-13, 2023, in Kansas City, Mo.

Liminal BioSciences Inc., confirms that following close of markets on April 4, 2023, the Board of Directors of the Company received a non-binding proposal from Structured Alpha LP outlining a potential transaction to acquire all of the issued and outstanding common shares of the Company that SALP does not currently own for US$7.50 in cash per common share.